股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國資源交通集團有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00269 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.2 HKD | | 4,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.2 HKD | | 4,000,000,000 | 本月底法定/註冊股本總額： HKD ...

预计至2025年年底净资产为负，顾地科技（002694）日前公告称，公司股票交易可能被实施退市风险警示。2月2日开盘，顾地科技股价"一字"跌停，截至 收盘报3.33元/股。 原子公司跨界文旅"埋雷" 公开资料显示，顾地科技是我国难燃PVC电工管和线槽的发明者和制造者，也曾是推动我国塑胶管道"以塑代钢"的先行者。公司的PE、PP、PVC三大系 列管道产品产品广泛应用于建筑内给排水、市政给水、燃气、建筑采暖、市政排水排污等领域。 2016年，顾地科技跨界文旅，并于2017年继续在赛事文旅业务上加码。当年7月，公告拟通过全资子公司阿拉善盟梦想汽车文化旅游开发有限公司（简 称"梦汽文旅"）投资约10亿元，实施阿拉善沙漠梦想汽车航空乐园-汽车乐园建设项目。遗憾的是，高投入没能带来高回报，反让顾地科技深陷泥潭。 公告显示，因梦汽文旅相关人格混同案件，顾地科技仍有两笔大额计提。 顾地科技股价走势图 涉诉大额计提拖垮公司业绩 1月31日，顾地科技披露2025年度业绩预告称，预计公司2025年归母净利润为亏损3亿元至5.77亿元，扣非后净利润为亏损6320.85万元至1.23亿元。 据披露，顾地科技2025年归属于母公司所有者 ...

奇瑞集团公布了2026年首月成绩单，总销量突破20万辆，达到200269辆。其中，新能源汽车销量达 到了52131辆，出口量同比增长了48.1%，达到了119605辆。 ...

Core Viewpoint - *ST Shuangcheng (002693.SZ) is expected to turn a profit in 2025, with net profit attributable to shareholders projected between 16 million to 23 million yuan, marking a significant turnaround from losses in the previous year [1] Financial Performance - The company anticipates a total profit growth of 107.53% to 111.30% year-on-year, with net profit attributable to shareholders expected to increase by 120.43% to 129.37% [1] - Revenue is projected to be between 250 million to 290 million yuan [1] Factors Influencing Profit Changes - The company is focusing on international development to counteract domestic drug price declines, leading to steady growth in export sales and advancements in overseas R&D projects [1] - The approval of the U.S. registration application for injectable paclitaxel (albumin-bound) is expected to drive significant revenue growth following its rapid sales post-approval [1] - The absence of fair value loss from Zhongrong Trust financial products, which impacted the previous year's results, and a reduction in asset impairment losses have also contributed to the turnaround [1]

Core Viewpoint - *ST Shuangcheng (002693.SZ) has been recognized as a high-tech enterprise in Ningbo for the first batch of 2025, which will provide tax benefits for the next three years [1] Group 1: Company Recognition - Ningbo Shuangcheng Pharmaceutical Co., Ltd., a subsidiary of Hainan Shuangcheng Pharmaceutical Co., Ltd., has been certified as a high-tech enterprise by the Ningbo Municipal High-tech Enterprise Recognition Management Work Leading Group [1] - The high-tech enterprise certificate number is GR202533101446, issued on December 8, 2025, and is valid for three years [1] Group 2: Tax Benefits - Following the recognition, Ningbo Shuangcheng will enjoy a preferential corporate income tax rate of 15% for three consecutive years, as per the relevant provisions of the Corporate Income Tax Law of the People's Republic of China [1] Group 3: Impact on Financial Performance - The recognition will not have an impact on the company's current operating performance [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國資源交通集團有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00269 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | HKD | | 0.2 | HKD | | 4,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | 20,000,000,000 | HKD | | 0.2 | HKD | | 4,000,000,000 | 本月底法定/註冊股本總額： H ...

Group 1 - The core point of the article is that *ST Shuangcheng (002693.SZ) has received FDA approval for its injectable bortezomib ANDA product [1] Group 2 - The company announced the FDA approval on its investor interaction platform [1]

Group 1 - The core viewpoint of the article is that *ST Shuangcheng (002693.SZ) has confirmed that several of its products are included in the medical insurance catalog [1] - The products that are included in the medical insurance catalog are: Thymosin injection, Somatostatin injection, Famotidine injection, Clindamycin hydrochloride injection, Chuanxiong phosphate injection, and Octreotide acetate injection [1] - The company has not submitted an application for its product, Paclitaxel injection (albumin-bound), in the domestic market [1]

Core Viewpoint - Hainan Shuangcheng Pharmaceutical Co., Ltd. has received FDA approval for its injectable Bortezomib ANDA, marking a significant milestone in its international expansion and product portfolio enhancement [1] Group 1: Company Performance - As of December 18, 2025, *ST Shuangcheng (002693) closed at 6.58 yuan, down 0.3% from the previous trading day, with a total market capitalization of 2.729 billion yuan [1] - The stock opened at 6.59 yuan, reached a high of 6.79 yuan, and a low of 6.55 yuan, with a trading volume of 32.0879 million yuan and a turnover rate of 1.17% [1] Group 2: Regulatory Approvals - The injectable Bortezomib ANDA has been recognized by the FDA as being bioequivalent and therapeutically equivalent to the reference drug [1] - The product has also received approval from the National Medical Products Administration of China and has passed the consistency evaluation, along with obtaining listing permission from Australia's TGA [1] Group 3: Strategic Implications - The FDA approval signifies that the company's product meets international standards, which is expected to enhance its international influence and operational performance [1] - This development will enrich the company's international sales product line and advance its globalization strategy [1] - The announcement also notes that overseas sales may be affected by regulations, policies, market conditions, and exchange rate fluctuations [1]

Core Viewpoint - The company *ST Shuangcheng has received approval from the U.S. FDA for its abbreviated new drug application (ANDA) for injectable bortezomib, indicating that the product is bioequivalent and therapeutically equivalent to the reference drug [1] Group 1: FDA Approval - The U.S. FDA has completed a comprehensive technical review of the ANDA submitted by the company [1] - The approval confirms that the company's product is equivalent in terms of biological and therapeutic effects to the original drug [1] Group 2: Approved Indications - The approved indications for the injectable bortezomib include: 1. Treatment of previously untreated multiple myeloma patients who are not suitable for high-dose chemotherapy, in combination with melphalan and prednisone [1] 2. Part of a combination therapy for previously untreated multiple myeloma patients under 65 years old, used for high-dose chemotherapy with autologous stem cell rescue following prior induction therapy [1] 3. Treatment for multiple myeloma patients who have received at least one prior therapy and whose disease has progressed [1] 4. Treatment of adult patients with previously untreated mantle cell lymphoma in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone [1]